Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Annals of Surgical Oncology

• Publication date

  2010-04-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1245/s10434-010-1104-2PMID 20429035
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters.

  2010cited by this paper
• Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.

  2009cited by this paper
• Tumor necrosis factor (TNF) biology and cell death.

  2008cited by this paper
• Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution’s Experience with 52 Patients

  2008cited by this paper
• TNF-Based Isolated Limb Perfusion Followed by Consolidation Biotherapy with Systemic Low-dose Interferon Alpha 2b in Patients with In-transit Melanoma Metastases: A Pilot Trial

  2008cited by this paper
• Long-term Results of Hyperthermic, Isolated Limb Perfusion for Melanoma: A Reflection of Tumor Biology

  2007cited by this paper
• Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.

  2007cited by this paper
• Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.

  2006cited by this paper
• Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

  2006cited by this paper
• Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.

  2006cited by this paper
• Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.

  2005cited by this paper
• Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas

  2005cited by this paper
• TNF dose reduction in isolated limb perfusion.

  2005cited by this paper
• One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases

  2004cited by this paper
• Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases

  2004cited by this paper
• Isolated limb perfusion for unresectable melanoma of the extremities.

  2004cited by this paper
• Isolated Limb Perfusion Prolongs the Limb Recurrence-Free Interval After Several Episodes of Excisional Surgery for Locoregional Recurrent Melanoma

  2004cited by this paper
• Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials.

  2003cited by this paper
• A Simplified Procedure for Continuous Intraoperative External Monitoring of Systemic Leakage during Isolated Limb Perfusion

  2002cited by this paper
• Isolated limb perfusion in locally advanced cutaneous melanoma.

  2002cited by this paper
• Factors Affecting Survival After Complete Response to Isolated Limb Perfusion in Patients With In-Transit Melanoma

  2001cited by this paper
• Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.

  2001cited by this paper
• Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

  2000cited by this paper
• Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma.

  1999cited by this paper
• Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

  1999cited by this paper
• Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

  1998cited by this paper
• Thirty‐five years of isolated limb perfusion for melanoma: Indications and results

  1996cited by this paper
• Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.

  1996cited by this paper
• Characterization of human recombinant tumor necrosis factor-alpha antiproliferative effects on human cells in culture.

  1988cited by this paper
• Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions.

  1982cited by this paper

• Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis.

  2025cites this paper
• Isolated Limb Perfusion and Immunotherapy in the Treatment of In-Transit Melanoma Metastases: Is It a Real Synergy?

  2024cites this paper
• Therapeutic Treatment Options for In-Transit Metastases from Melanoma

  2024cites this paper
• The Diagnosis and Management of Cutaneous Metastases from Melanoma

  2023cites this paper
• Non-Operative Options for Loco-regional Melanoma.

  2021cites this paper
• Role of Isolated Limb Perfusion in the Era of Targeted Therapies and Immunotherapy in Melanoma. A Systematic Review of The Literature

  2021cites this paper
• Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study.

  2019cites this paper
• A systematic review and meta‐analysis of locoregional treatments for in‐transit melanoma

  2019cites this paper
• Isolated Limb Perfusion and Infusion in the Management of In-Transit Melanoma of the Extremities: Modern Data Affecting Practice

  2019cites this paper
• Perfusão regional de membros no tratamento quimioterápico de melanoma: uma revisão de literatura

  2019influential citation
• Hyperthermic Regional Perfusion for Melanoma of the Limbs

  2018cites this paper
• Management of Melanoma Locoregional Recurrence

  2018cites this paper
• Läsionale Therapieoptionen beim maligen Melanom

  2018cites this paper
• Treatment of Metastatic Melanoma

  2018cites this paper
• Diagnosis and treatment of in-transit melanoma metastases.

  2017cites this paper
• Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients

  2017cites this paper
• Normal human CD4+ helper T cells express Kv1.1 voltage-gated K+ channels, and selective Kv1.1 block in T cells induces by itself robust TNFα production and secretion and activation of the NFκB non-canonical pathway

  2016cites this paper
• Isolated Limb Perfusion for Stage III Melanoma: Does It Still Have a Role in the Present Era of Effective Systemic Therapy?

  2016cites this paper
• Perfusion and infusion for melanoma in-transit metastases in the era of effective systemic therapy.

  2015cites this paper
• The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options

  2015cites this paper
• Isolated limb perfusion for in‐transit melanoma metastases: Melphalan or TNF‐melphalan perfusion?

  2014cites this paper
• Subcutaneous metastases from melanoma: a discussion of clinical experience.

  2014cites this paper
• Current Treatment of Locoregional Recurrence of Melanoma

  2013cites this paper
• Death receptors as targets in cancer

  2013cites this paper
• Isolated regional perfusion for metastases of malignant melanoma - Clinical and experimental studies

  2013cites this paper
• Melanoma M (Zero): Diagnosis and Therapy

  2013cites this paper
• Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma

  2013cites this paper
• Tumors of the Skeletal System

  2012cites this paper
• Electrochemotherapy for disseminated superficial metastases from malignant melanoma

  2012cites this paper
• Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role?

  2012cites this paper
• Hyperthermic Pelvic Perfusion With Tumor Necrosis Factor-&agr; for Locally Advanced Cancers: Encouraging Results of a Phase II Study

  2012cites this paper
• Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion

  2011cites this paper
• Long‐term outcome of isolated limb perfusion with tumour necrosis factor‐α for patients with melanoma in‐transit metastases

  2011cites this paper
• Antigen-specific versus Antigen-nonspecific Immunotherapeutic Approaches for Human Melanoma: The Need for Integration for Optimal Efficacy?

  2011cites this paper
• Cutaneous Metastases from Malignant Melanoma: Clinical Features and New Therapeutic Perspectives

  2011cites this paper
• Challenging Problems in the Surgical Management of Melanoma

  2011cites this paper
• 20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters

  2011cites this paper
• Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha

  2011cites this paper
• Melanoma immunotherapy.

  2010cites this paper